Skip to Content

Generic Zipsor Availability

Zipsor is a brand name of diclofenac, approved by the FDA in the following formulation(s):

ZIPSOR (diclofenac potassium - capsule;oral)

  • Manufacturer: DEPOMED INC
    Approval date: June 16, 2009
    Strength(s): 25MG [RLD] [AB]

Has a generic version of Zipsor been approved?

A generic version of Zipsor has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zipsor and have been approved by the FDA:

diclofenac potassium capsule;oral

  • Manufacturer: BIONPHARMA INC
    Approval date: February 23, 2016
    Strength(s): 25MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zipsor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Oral liquid compositions
    Patent 6,287,594
    Issued: September 11, 2001
    Inventor(s): Wilson; Edward S. & Trespidi; Laura A. & Clark; Christy M. & Desai; Ashok J. & Meyer; Glenn A.
    The present invention relates to novel, liquid and semi-solid pharmaceutical compositions which can be administered in liquid form or can be used for preparing capsules containing such pharmaceutical compositions. Also provided are methods of using and processes for preparing the pharmaceutical compositions of the present invention.
    Patent expiration dates:
    • January 15, 2019
      ✓ 
      Drug product
  • Oral liquid compositions
    Patent 6,365,180
    Issued: April 2, 2002
    Inventor(s): Glenn A.; Meyer & Laura A.; Trespidi & Edward S.; Wilson & Christy M.; Clark & Ashok J.; Desai & Frederick D.; Sancilio
    The present invention relates to novel, liquid and semi-solid pharmaceutical compositions which can be administered in liquid form or can be used for preparing capsules containing such pharmaceutical compositions. Also provided are methods of using and processes for preparing the pharmaceutical compositions of the present invention.
    Patent expiration dates:
    • July 15, 2019
      ✓ 
      Patent use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
      ✓ 
      Drug product
  • Method of treating post-surgical acute pain
    Patent 7,662,858
    Issued: February 16, 2010
    Inventor(s): Kowalski; Mark M. & Young; James L. & Moore; Keith A.
    Assignee(s): aaiPharma, Inc.
    A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.
    Patent expiration dates:
    • February 24, 2029
      ✓ 
      Patent use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
  • Method of treating post-surgical acute pain
    Patent 7,884,095
    Issued: February 8, 2011
    Inventor(s): Kowalski; Mark M. & Young; James L. & Moore; Keith A.
    Assignee(s): aaiPharma Inc.
    A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.
    Patent expiration dates:
    • February 24, 2029
      ✓ 
      Patent use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
  • Method of treating post-surgical acute pain
    Patent 7,939,518
    Issued: May 10, 2011
    Inventor(s): Kowalski; Mark M. & Young; James L. & Moore; Keith A.
    Assignee(s): Aaipharma Inc.
    A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.
    Patent expiration dates:
    • February 24, 2029
      ✓ 
      Patent use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
  • Method of treating post-surgical acute pain
    Patent 8,110,606
    Issued: February 7, 2012
    Inventor(s): Kowalski; Mark M. & Young; James L. & Moore; Keith A.
    Assignee(s): Aaipharma Services Corp.
    A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.
    Patent expiration dates:
    • February 24, 2029
      ✓ 
      Patent use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
  • Method of treating post-surgical acute pain
    Patent 8,623,920
    Issued: January 7, 2014
    Assignee(s): Depomed, Inc.
    A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.
    Patent expiration dates:
    • February 24, 2029
      ✓ 
      Patent use: DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide